Long Position on TARS @ $29.25 on 2/8/2024 (Momentum)

Tarsus Pharmaceuticals, Inc. (TARS), a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.

Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.

In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Please note, this stock reports earnings on March 11.

Tarsus Pharmaceuticals, Inc. reported a loss of $1.28 per share on revenue of $1.87 million for the third quarter ended September 2023. The consensus estimate was a loss of $1.40 per share on revenue of $0.40 million. The company beat consensus estimates by 8.57%.

As analysts raise the price target of the stock and with share prices rising over the last few weeks, share prices should head higher. 

Entry Point: $29.25

Trading Range: $11.33 - $30.00

Stop Loss: $27.80

Target Price: $32.15

Position closed on 2/23/2024 at price of $32.00 with a 9.40% gain in 15 days.

Back to Portfolio